Trial site
Institutul de pneumoftiziologie Marius Nasta
Bucharest, 050152, RomaniaEU-13 widening countryNot linked to an institution yet
- 16running trials
- 10closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 318 trials
- Phase 26 trials
- Phase 1/21 trial
- Phase 41 trial
- Status
- Completed10 trials
- Active, not recruiting7 trials
- Recruiting5 trials
- Not yet recruiting4 trials
- Lead sponsor
- AstraZeneca4 trials
- Chiesi Farmaceutici S.p.A.3 trials
- Boehringer Ingelheim2 trials
- GlaxoSmithKline2 trials
- Novartis Pharma AG2 trials
- and 11 more
Running trials
Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
NCT07931495· Phase 3· Novo Nordisk A/S· Source
Recruiting
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
2022-502365-26-00· Phase 3· Novartis Pharma AG· Source
Recruiting
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
NCT07666490· Phase 4· Chiesi Farmaceutici S.p.A.· Source
Recruiting
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
NCT07284602· Phase 3· PureTech· Source
Recruiting
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033· Phase 3· GlaxoSmithKline· Source
Recruiting
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
NCT07230288· Phase 2· AbbVie· Source
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
2024-513613-12-00· Phase 1/2· Novartis Pharma AG· Source
Active, not recruiting
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
NCT06736990· Phase 2· Calluna Pharma AS· Source
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053· Phase 2· GlaxoSmithKline· Source
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966· Phase 3· AstraZeneca· Source
Active, not recruiting
A study to investigate the efficacy and safety of tezepelumab compared with placebo in children 5 to < 12 years old with severe asthma
2022-502984-39-00· Phase 3· AstraZeneca AB· Source
Active, not recruiting
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
NCT05562466· Phase 3· Novartis Pharmaceuticals· Source
Enrolling by invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186· Phase 3· United Therapeutics· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error